Clinical trial · Observational
CT and MRI in Prediction of Response in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy and/or Immunotherapy
Clinical Study of CT and MRI in Prediction of Response in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy and/or Immunotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective and observational clinical study for seeking out a better way to predict the pathologic complete response (pCR) in patients with advanced gastric cancer (AGC) based on the post-neoadjuvant treatment Magnetic Resonance Imaging (MRI) and CT data. This study will help the surgeons to better formulate treatment regimens for gastric cancer in the clinical practice.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Magnetic Resonance Imaging | — | UNRESOLVED | — |
| Neoadjuvant Chemotherapy | — | UNRESOLVED | — |
| Neoadjuvant Immunotherapy | — | UNRESOLVED | — |
| Tomography, X-Ray Computed | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PD-1 inhibitor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Single Group Assignment
- description
- Patients with AGC who underwent neoadjuvant immunotherapy and/or chemotherapy would recieve MRI and CT examination before and after 3 cycles treatment.
- interventionNames
- Drug: PD-1 inhibitor
Primary outcomes (1)
- measure
- Predictive value of CT and MRI after the neoadjuvant treatment for developing a pCR at surgery
- timeFrame
- up to 2 year
- description
- Predictive value of CT and MRI after the neoadjuvant treatment for developing a pathologic complete response at surgery (Grade 0 - no viable cancer cells seen in the resection specimen).
Secondary outcomes (3)
- measure
- Predictive value of CT and MRI after the neoadjuvant treatment for pathologic T staging
- timeFrame
- up to 2 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 18 Years to 80 Years 2. Consecutive patients with preoperative pathologically confirmed AGC by endoscopy and preoperative imaging data (CT/MRI) were included. 3. Clinical staging Ⅱ-Ⅲ according to the UICC/AJCC 8th guideline for gastric cancer without distant metastasis. 4. Suitable for pre-operative chemotherapy, immunotherapy and surgical resection 5. No contraindications for CT/MRI examination. 6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. 7. The patients participate in this study with informed consent. Exclusion Criteria: 1. Patients with a history of previous chemotherapy or immunotherapy. 2. The patients couldn't perform MSCT or MR scanning or artefacts affect the evaluation. 3. The patients are extremely anxious and uncooperative about surgery or neoadjuvant therapy. 4. The patients refuse to participate in the project. 5. Pregnancy, lactation or inadequate contraception 6. Pacemaker or implanted defibrillator 7. Patients with a history of psychological illness or condition such as to interfere with the patient's ability to understand requirements of the study. 8. Other situations considered by investigators, which not meet the inclusion criteria.
References
Publications (0)
Data not yet available